{
  "id": 3261139,
  "title": "Earnings call transcript: Vipshop Q2 2026 profit miss weighs on shares",
  "url": "https://urgent.news/2026/08/25/earnings-call-transcript-vipshop-q2-2026-profit-miss-weighs-on-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-25T12:32:30.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-vipshop-q2-2026-profit-miss-weighs-on-shares-93CH-4875316"
  },
  "original_language": "en",
  "account": "Vipshop Holdings reported weaker-than-expected second-quarter 2026 earnings, missing analyst forecasts on both profit and revenue. The company's earnings per diluted ADS were $2.91, below the $3.94 forecast, while revenue stood at $24.71 billion, slightly below the $24.88 billion estimate. Premarket trading saw Vipshop shares drop 2.93% to $13.90, nearing the lower end of its 52-week range. The earnings miss was primarily due to higher fulfillment costs, rising return rates, and a challenging retail environment in China. Gross margin remained steady at 23.3%, but operating income weakened as revenue fell and fixed costs were spread across a smaller base. GAAP net income surged to RMB 4.3 billion, driven by a one-time investment gain, while non-GAAP net income fell to RMB 392.2 million. The company's outlook for the rest of 2026 remains cautious, with guidance pointing to a slight decline in revenue and slightly negative full-year revenue compared to 2025. Vipshop highlighted strong SVIP membership growth, a larger buyback plan, and continued momentum at Shan Shan Outlet as key growth drivers.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Earnings call transcript: FluoGuide advances U.S. cancer trial setup in H1 2026",
        "url": "https://urgent.news/2026/08/25/earnings-call-transcript-fluoguide-advances-u-s-cancer-trial-setup-in",
        "published": "2026-08-25T12:33:35.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}